These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 16804994)
1. [What opportunities are afforded by enzyme replacement therapy]. Huppertz HI Z Rheumatol; 2006 Feb; 65(1):44-5. PubMed ID: 16804994 [No Abstract] [Full Text] [Related]
2. [Care in the treatment of orphan diseases at home]. Bénévise N Soins; 2003; (672):49-51. PubMed ID: 12655827 [No Abstract] [Full Text] [Related]
3. The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease. Hollak CE; Weinreb NJ Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):205-18. PubMed ID: 25987174 [TBL] [Abstract][Full Text] [Related]
4. [High cost drugs for rare diseases in Brazil: the case of lysosomal storage disorders]. de Souza MV; Krug BC; Picon PD; Schwartz IV Cien Saude Colet; 2010 Nov; 15 Suppl 3():3443-54. PubMed ID: 21120332 [TBL] [Abstract][Full Text] [Related]
5. [How does the landscape change in lysosomal storage disease]. Parini R Pediatr Med Chir; 2007; 29(5):275-8. PubMed ID: 18402399 [No Abstract] [Full Text] [Related]
6. Lysosomal storage disorders: Novel and frequent pathogenic variants in a large cohort of Indian patients of Pompe, Fabry, Gaucher and Hurler disease. Thomas DC; Sharma S; Puri RD; Verma IC; Verma J Clin Biochem; 2021 Mar; 89():14-37. PubMed ID: 33301762 [TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy in Gaucher's and Fabry's disease. Pentchev PG Ann Clin Lab Sci; 1977; 7(3):251-3. PubMed ID: 404951 [TBL] [Abstract][Full Text] [Related]
9. [Enzyme replacement therapy for lysosomal storage disorders]. Valayannopoulos V; Brassier A; Chabli A; Caillaud C; Lemoine M; Odent T; Arnoux JB; de Lonlay P Arch Pediatr; 2011 Oct; 18(10):1119-23. PubMed ID: 21873040 [TBL] [Abstract][Full Text] [Related]
10. [Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary]. Szegedi M; Molnár MJ; Boncz I; Kosztolányi G Orv Hetil; 2014 Nov; 155(44):1735-41. PubMed ID: 25344850 [TBL] [Abstract][Full Text] [Related]
11. Recent advances and novel treatments for sphingolipidoses. Arenz C Future Med Chem; 2017 Sep; 9(14):1687-1700. PubMed ID: 28857617 [TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement for lysosomal diseases. Brady RO Annu Rev Med; 2006; 57():283-96. PubMed ID: 16409150 [TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy for lysosomal storage disorders: successful transition from concept to clinical practice. Sly WS Mo Med; 2004; 101(2):100-4. PubMed ID: 15119106 [TBL] [Abstract][Full Text] [Related]
15. [Gaucher disease, Fabry disease and mucopolysaccharidosis type I--how can the rheumatologist recognise these patients?]. Manger B; Menge E; Schaefer R; Haase C; Seidel J; Michels H Z Rheumatol; 2006 Feb; 65(1):32, 34-43. PubMed ID: 16467949 [TBL] [Abstract][Full Text] [Related]
16. Chemical chaperones--a new concept in drug research. Kolter T; Wendeler M Chembiochem; 2003 Apr; 4(4):260-4. PubMed ID: 12672104 [No Abstract] [Full Text] [Related]